Biotechnology company
VistaGen Therapeutics is putting humans first with Human Clinical Trials in a
Test Tube. This human pluripotent stem cell (hPSC) technology platform has been
developed to provide clinically relevant predictions of potential toxicity long
before drug candidates are ever tested on humans.
VistaGen’s hPSC-based
bioassay systems simulate human biology much more effectively than animal
testing and other nonclinical techniques and technologies currently used in
drug development. This superior approximation of human physiology enables
pharmaceutical companies to better predict potential pitfalls in promising drug
candidates during preclinical development – potentially saving millions of
dollars and countless hours. Many times, a drug candidate that showed great
promise during preclinical testing ultimately fails in human trials due to
unforeseen heart or liver toxicity or metabolism issues. That quickly, a
potentially lifesaving drug candidate is lost to the world. Thanks to
VistaGen’s pioneering efforts, however, the limitations of animal and in vitro
testing have been overcome and once-promising drug candidates can potentially
have a second chance to be brought successfully through clinical trials.
Human Clinical Trials in a
Test Tube provides priceless toxicology prediction screening long before human
subjects ever encounter a drug. With this hPSC technology, VistaGen can not
only help pharmaceutical companies enjoy greater success in their drug
development efforts, but the company can also create its own diverse pipeline
of new proprietary drug rescue variants, revisiting discontinued small-molecule
candidates that were shelved due to adverse reactions in humans.
VistaGen is currently
developing two predictive biological assay systems: CardioSafe 3D and LiverSafe
3D. CardioSafe 3D uses mature human heart cells derived from hPSCs to screen
for heart toxicity in connection with the company’s drug rescue activities.
LiverSafe 3D, being developed in collaboration with leading stem cell researcher
Dr. Gordon Keller, will similarly offer valuable predictive screening data
relating to liver toxicity and metabolism issues.
For more information about
VistaGen and its advancements, visit www.VistaGen.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
